MandalMed Inc Profile last edited on: 4/23/19
CAGE: 472C9
UEI: NPGNAQVJ3VZ7
Business Identifier: Biomedicine 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 12
County: San Francisco
Congr. District: 12
County: San Francisco
Public Profile
Originally dba as MandalMed Inc, the firm had a business model organized around out-licensing and, to be cost effective, use of non-US faciilities to undertake clinical trials, The firm also indicated intent to form alliances with external players to undertake on their behalf late stage clinical trials, sales, and marketing of the first pharmaceutical products. Though still in receipt of SBIR funding, the firm's site is no longer operational and a single-page site indicates a new name - Bioscience Laboratories - and a shift in the firm's focus.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2018 | 1 | NIH | $299,900 | |
| Project Title: Biologic Inhibitor of Galectin-3 for Liver Fibrosis | ||||
| 2018 | 2 | NIH | $2,225,316 | |
| Project Title: Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | ||||
| 2013 | 1 | NIH | $299,958 | |
| Project Title: Protein Inhibitor Of Galectin-3 To Limit Fibrosis After Myocardial Infarction | ||||
| 2011 | 1 | NIH | $250,000 | |
| Project Title: Model Of The Human Testis For Reproductive Toxicology | ||||
| 2008 | 1 | NIH | $363,936 | |
| Project Title: Preclinical Testing Of Galectin-3c For Multiple Myeloma | ||||
Key People / Management
Constance M John -- President
Mario C Castellon -- Member, Board of Directors
Maurizio Chiriva-Internati
Deborah E Hall
Constance M S John
Alpa Trivedi -- Director, Molecular Biology
Mario C Castellon -- Member, Board of Directors
Maurizio Chiriva-Internati
Deborah E Hall
Constance M S John
Alpa Trivedi -- Director, Molecular Biology
